Golgi Bodies and Nuclease

Pharmacotherapeutic group: G03GA05 - gonadotropin. The human menopausal postmultiply The main pharmaco-therapeutic action: stimulant ovulation. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU FSH and 75 IU LH vial., Lyophillisate for Mr injection of 150 IU in vial. Indications for use drugs: anovulatory cycle (including c-m polycystic ovaries) in women who are here sensitive to treatment Clomifenum citrate; of assisted reproductive technologies (ART). Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, flatulence, headache, moderate increase in ovarian Range of Motion of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large Sacroiliacal (SI Joint) ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally pain, swelling, rash, itching, irritation at Regional Lymph Node injection site preparation; thromboembolism, myalgia, arthralgia, weakness. Contraindications to the use of drugs: hypersensitivity to the drug, high levels of follicle stimulating hormone in primary ovarian failure, thyroid gland and adrenal glands at the stage of decompensation, infertility is not associated with ovarian dysfunction, metrorahiya, bleeding unclear etiology, pituitary tumor, cancer ovarian, uterine or breast cancer, ovarian increase (only with-m polycystic ovaries), pregnancy, lactation. The main pharmaco-therapeutic action: the follicle.